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Haematologica has published European guidelinesfor empirical and targeted antibacterial therapy forfebrile neutropenic patients in the era of emerging
resistance (ECIL-4). Indeed, collateral damage by broad-
spectrum antibiotic therapy includes selection of multidrug
resistant pathogens, and increased predisposition to infec-
tion by fungi and Clostridium difficile. Antibiotic resistance
has become a major public health concern, with fears
expressed that we will soon run out of antibiotics.1
This is critically important for the management of hema-
tologic cancer patients who receive consecutive courses of
immunosuppressive treatments, resulting in varying
degrees and durations of neutropenia. During immunosup-
pressive therapy, many patients will develop fever and are
prescribed antibiotics for prevention or treatment of infec-
tion. 
Several recent studies have shown an increasing preva-
lence of multidrug-resistance among Gram-negative
pathogens in hematology patients. In one recent prospec-
tive observational study, the only independent risk factors
for the acquisition of multiresistant pathogens were prior
antibiotic exposure (OR 3.57; 95%CI: 1.63-7.80) and uri-
nary catheterization (OR 2.41; 95%CI: 1.01-5.74).2
The use of broad-spectrum antibiotics also is a well-
known risk factor for invasive fungal infection in hematol-
ogy patients. Chronic disseminated candidiasis in patients
with acute leukemia and/or bone marrow transplantation
has been independently associated with the use of
quinolone antibiotics in particular,3 and a recent observa-
tional study showed that 92% of patients with candidemia
had received broad-spectrum antibiotics.4 Important risk
factors for C. difficile-associated disease in hematology
patients include the number and duration of antibiotics
received, with particular risk attached to certain classes,
such as cephalosporins.5
For all these reasons, it is becoming more and more nec-
essary to optimize antibiotic use in hematology patients,
and to deploy antimicrobial stewardship strategies that
have shown benefit in other categories of patients. Key
components of stewardship include: i) de-escalation of
broad empirical regimens once the pathogen is identified;
ii) dose optimization in critically-ill patients;6 and iii) the
long tradition of prudent antibiotic use in Northern
European countries which is reflected in their low resist-
ance rates, as shown in, for example, the European
Antimicrobial Resistance Surveillance Network EARS-
Net.7
Antimicrobial stewardship aims to limit the unnecessary
use of broad-spectrum antibiotics and involves a continu-
ous effort by healthcare institutions to optimize antimicro-
bial use in hospitalized patients. Its targets are to improve
outcomes, ensure cost-effective therapy, and to reduce
adverse effects of antimicrobial use, including resistance.8
Control of infection is closely related to antimicrobial
stewardship programs, as it aims to prevent the spread of
the resistant organisms, when these are selected locally or
introduced via patient transfers. The successful implemen-
tation of antimicrobial stewardship and infection control
programs complement each other in limiting the number
of infections caused by multidrug-resistant organisms. 
Infection control strategies found their way into hema-
tology many years ago, and guidelines in this field are pub-
lished elsewhere.9 The most important measures in hema-
tology are: i) enforcement of hand hygiene by using alco-
hol-based hand-rubs; ii) standard barrier precautions; iii)
enforcement of isolation criteria for patients colonized or
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infected with multidrug-resistant organisms, e.g. methi-
cillin-resistant Staphylococcus aureus (MRSA) or Extended-
Spectrum Beta-lactamase (ESBL)-producing organisms; iv)
cohorting of infected patients; v) the use of single rooms
for hematologic stem cell transplant (HSCT) recipients; and
vi) High-Efficiency Particulate Air (HEPA) filtration for allo-
geneic HSCT recipients.10 Antisepsis with alcohol-based
hand-rubs is the single most effective hygienic measure in
healthcare institutions and has led to a reduction in overall
nosocomial (hospital-acquired) infection and MRSA trans-
mission.11
There are several key aspects to implementing antimi-
crobial stewardship for hematologic cancer patients. These
require collaboration between the hematologist/oncolo-
gist, the microbiology laboratory, hospital pharmacy and
an infectious diseases (ID) consultation service. 
1) Local surveillance of antibiotic resistance, antibiotic con-
sumption and patient outcomes, including monitoring reports.
Local surveillance in hematology/oncology centers
should be carried out, with a review of the situation twice
yearly. It includes data on the identity and resistance pat-
terns of blood isolates. Indicator organisms, or a ‘top 10’
list of relevant pathogens should be defined. These are
likely to include the Gram-negative bacteria, Escherichia
coli, Klebsiella, Pseudomonas aeruginosa, Enterobacter, Serratia
and Acinetobacter, and the Gram-positives S. aureus, coagu-
lase-negative staphylococci, Enterococcus and alpha-
hemolytic streptococci. In addition, antibiotic consump-
tion should be monitored, preferentially as Defined Daily
Doses (DDD)/100 patient days or Days on Therapy
(DOT) to allow for comparisons with other centers.12 The
DOT unit is particularly useful for pediatric populations. 
Policy decisions need also to be made: i) whether or not
to use antibiotic prophylaxis in certain categories of
patients; ii) the need and frequency of surveillance cultures
to detect colonization, especially when antibiotic prophy-
laxis is used.10 Good surveillance data allow for fast and
targeted adaptation of empirical regimens and/or prophy-
laxis.13 Resistance patterns of colonizing microorganisms
are often, but not always, indicative of the resistance pat-
terns of subsequent blood isolates in these patients.
Microbiological investigation of likely infections should
always be carried out, irrespective of what is known or
suspected from previous surveillance cultures. In addition,
outcome data for bacteremic patients (ICU stay, total
length of stay, total and attributable mortality) of the
hematology unit should also be collected to determine and
review the coverage and adequacy of the local empirical
antibiotic regimens. Colonization with resistant organ-
isms should impact the choice of empirical therapy regi-
mens only if these organisms have caused significant mor-
bidity and mortality in previous hematology patients. 
2. Multidisciplinary protocols and algorithms on the diagnosis,
prevention and treatment of infections should be developed in col-
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Table 1. Principles of antimicrobial stewardship for hematology patients.
– The initiation of empirical antibiotic treatment should be prompted by fever and clinical signs, and not by C-reactive protein or other biomarkers, as stud-
ies of these have shown inconsistent results;10 antibiotics should not be initiated on the basis of colonization by resistant organisms.
– Empirical antibiotic treatment should never be started or changed before taking at least two blood cultures, along with relevant specimens from the clin-
ically-suspected sites of infection 
– Risk stratification (low/high risk) for infection should be undertaken according to the Multinational Association for Supportive Care in Cancer (MASCC)
score,14 and should be considered in the empirical therapy algorithm10
– The spectrum of initial empirical therapy should, at the very least, cover common virulent Enterobacteriaceae (Escherichia coli and Klebsiella pneumo-
niae), also Pseudomonas aeruginosa, and, depending on the setting, and/or prophylaxis strategies, S. aureus including MRSA, but not coagulase-negative
staphylococci.
– Individualized risk assessment for multi-resistant pathogens should guide the development of the management algorithms.2 
– Strategies to reassess empirical antibiotic therapy after 2-3 days (i.e. once microbiology results are available) should be implemented, with de-escalation
if possible. 
– The algorithms should guide treatment duration, as outlined in point 2.
– Individualized risk assessments for infection can be undertaken, e.g. identifying clinical parameters that have been associated in the literature with a risk
for secondary infection after a first episode of fever and neutropenia.15
Table 2. Summary of antimicrobial stewardship recommendations for hematology patients.
1. Produce epidemiological data on blood isolates and colonization cultures (especially if prophylaxis is used) on a regular basis. 
2. Record infection-related outcome data (length of stay, infection-related mortality).
3. Discuss microbiology, antibiotic use and outcome data in a local multidisciplinary working group/policy committee consisting of hematologists/ ID physi-
cians/microbiologists/ID pharmacists.
4. Develop multidisciplinary protocols and algorithms on diagnosis, treatment and prophylaxis of fever during neutropenia, including on duration of therapy
for the inpatient as well as outpatient management.
5. Provide ID training for hematologists and clinical hematology training for ID physicians/microbiologists and pharmacists.
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laboration with ID specialists and medical microbiologists and up-
dated to reflect changes in bacterial antimicrobial susceptibilities in
the unit. 
Once the local surveillance data are available, they should
be used to develop or adapt local protocols and algorithms.
A few important principles to be considered are listed in
Table 1. 
3. Swift reporting of positive clinical cultures and implementation
of rapid techniques for bacterial identification and resistance pat-
terns by the microbiology laboratory to control the duration of treat-
ment and to facilitate re-assessment of the antibiotic therapy.
The speed of communicating microbiological results to
the clinicians by the laboratory is paramount for prompt
adaptation of antimicrobial regimens.16 Re-assessment of
empirical antimicrobial therapy with the help of the micro-
biological results after 2-3 days allows for de-escalation to
targeted, narrower-spectrum antibiotics appropriate to the
susceptibilities of the pathogens isolated. A clinical example
of de-escalation strategy is shown in the Appendix and
illustrates how de-escalation works in an individual patient.
For details and background of the prophylaxis strategy in
this example, see the method section of the publication by
Slobbe et al.17,18
Experience in the Netherlands has shown that broad-
spectrum empirical therapy in neutropenic fever can also be
replaced by narrower-spectrum oral agents, mitigating
selection for resistance. De Marie et al. and Cornelissen et al.
reported that intravenous (i.v.) antibiotics could be discon-
tinued early in febrile patients with persistent neutropenia
who received decontamination or oral regimens
(neomycin/polymyxin B or co-trimoxazole or ciprofloxacin
and an antifungal drug).19,20 Fifteen years later, Slobbe et al.
showed that, for the same category of high-risk patients, it
was safe to discontinue empirical imipenem for fever after
72 h if, following a standardized protocol, no infectious eti-
ology was documented.17 In the ECIL-4 guideline on empir-
ical therapy, the suggested duration of antimicrobial thera-
py is 72 h in stable patients who are afebrile for more than
48 h and have no microbiological or clinical documentation
of infection (see Averbuch et al. in this issue of
Haematologica21).
It should be stressed that, in the series described by
Slobbe et al., empirical antibiotics were stopped after 72 h
for patients on fluoroquinolone prophylaxis with meticu-
lous clinical and microbiological follow up, including twice-
weekly surveillance cultures and protective isolation with
alternative prophylactic oral antibiotics if surveillance cul-
tures detected ciprofloxacin-resistant Gram-negative bacte-
ria.17 Although prophylaxis with quinolones exerts a signif-
icant selection pressure for colonization and infection by
fluoroquinolone-resistant organisms, a recent Cochrane
review confirmed earlier meta-analyses that the reduction
in mortality and infection rates in high-risk patients still out-
weighs the risk of resistance, the costs and occasional
adverse events.22 Nevertheless, quinolone prophylaxis
should be employed only in selected high-risk patients, not
in all neutropenic patients.12,17
4. Optimization of dosing regimens using pharmacodynamic
principles. 
Individualization of antibiotic regimens according to: i)
minimal inhibitory concentration (MIC) data for the
causative pathogen in the individual or on local surveillance
data; and ii) patients’ characteristics, can optimize treat-
ment outcomes. This should benefit neutropenic patients
who have a malfunctioning immune system, and particular-
ly high-risk patients and those whose pathogens have only
borderline antibiotic susceptibility.23 Several pharmacologi-
cal issues should be taken into consideration.24 In particular,
high-risk hematologic patients have large volumes of distri-
bution and/or capillary leak syndrome and/or a more rapid
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Case
A 26-year old woman with acute myeloid leukemia has been treated with 2 remission-induction courses of chemotherapy. There has been no microbio-
logically or clinically documented infection during the induction phase, only fever of unknown origin. She is currently in complete remission and has been
hospitalized for consolidation therapy with high-dose cytarabine.
Today is Day 7 after the start of chemotherapy following which she is expected to be neutropenic (< 0.1x109/L) for at least ten days.
On Day -5 she was started on prophylactic ciprofloxacin 500 mg q12h, colistin 200 mg q6h and fluconazole 400 mg q24h orally. Colonization cultures ten
days after the start of prophylaxis showed no ciprofloxacin-resistant Gram-negative bacteria and no growth of S. aureus.
This morning at 7:30 am she has developed watery diarrhea. She experiences chills and rigors, and her body temperature quickly rises from 37.5°C at 8:00
am to 39.8°C at 10:00 am. She has no respiratory complaints, no obnubilation, and is not oliguric. On clinical examination, she has painful oral mucositis
grade II, multiple petechiae on the legs, and her blood pressure has dropped from 130/80 mmHg to 100/60 mmHg. She has a tunneled subclavia catheter;
the insertion site and tunnel are unremarkable. Her abdomen is distended but normal bowel sounds are heard at auscultation and palpation is only slightly
painful. The diagnosis of febrile neutropenia is made.
Hemoglobin is 9.3 g/dL; hematocrit 27.7%; neutrophil count less than 0.1x109/L and platelets 23x109/L. The rest of the laboratory tests and a chest X-ray are
unremarkable. According to the ward protocol, 1 set of blood cultures is drawn from the catheter, 2 sets of blood cultures are drawn by venipuncture and
urine is collected for culture. 
Piperacillin/tazobactam 4.5 g q8h iv is started.
The next day, the patient has clinically improved, but she is still febrile (38.5°C). The microbiology laboratory reports growth of Gram-positive cocci (pre-
sumably streptococci) from 5 out of 6 blood culture bottles drawn on Day 7. The day after (Day 9), the laboratory reports further identification of the iso-
lates: viridans streptococci, susceptible to penicillin. Piperacillin/tazobactam is stopped. Benzylpenicillin (penicillin G), 2MU q4h i.v. is administered
and ciprofloxacin and fluconazole prophylaxis is continued. All antimicrobial agents are stopped after ten days when the neutrophil count has risen to
more than 0.5x109/ L.
Appendix
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clearance of certain drugs. In general, higher doses are need-
ed to obtain adequate serum concentrations, and individual
pharmacokinetic variability is high. For some classes of
antibiotics, few pharmacokinetic data are available for
patients with fever and neutropenia. However, dosing regi-
mens may be predicted from other categories of patients
with large volumes of distribution such as ICU patients
with critical illness.24
Three patterns of antibiotic activity are important to con-
sider when defining the optimal dosage of different antibi-
otic classes:25
- concentration-dependent killing is seen for aminoglyco-
sides, with a considerable post-antibiotic effect; 
- beta-lactam antibiotics display time-dependent killing
with little or no post-antibiotic effect;
- quinolones and vancomycin have activity related to the
Area Under the time Concentration Curve (AUC):MIC
ratio, reflecting both the serum peak and the time above
MIC.
In the case of beta-lactams with short half-life, optimiza-
tion of dosing may be obtained by extending the infusion
time prolonging the period that the free-drug levels remain
above the MIC. Recent retrospective studies support this
optimized dosing in critically-ill patients,26,27 with relevant
data available for piperacillin-tazobactam, ceftazidime,
cefepime and meropenem.23 The choice of continuous ver-
sus extended infusion of beta-lactams should be guided by
the stability of the drug at room temperature.23
Aminoglycoside dosing is optimized via the administra-
tion of large (once daily) doses up to 7 mg/kg for gentamicin
and tobramycin and up to 20 mg/kg for amikacin, aiming at
a serum peak/MIC ratio of 8-12 (individual MIC or local
data), which also minimizes nephrotoxicity.28 Active thera-
peutic drug monitoring29 should be performed to avoid toxic
drug levels arising via accumulation. Optimization of van-
comycin dosing is achieved by using a loading dose (up to
35 mg/kg) and ensuring optimal trough levels of approxi-
mately 15 mg/L, either by twice-daily administration or
continuous infusion, in order to achieve an (AUC)0-24: MIC
ratio of more than 400, which correlates with positive out-
comes in patients with MRSA bacteremia.30 Nephrotoxicity
of vancomycin, which mainly occurs if they are combined
with other nephrotoxic drugs, should be monitored.31
5. Frequent multidisciplinary rounds. 
Clinical rounds, including discussion of patient histories
and interactive, bedside education on antimicrobial drug
use and infection control, are recommended. A summary of
recommendations is presented in Table 2.
In conclusion, antimicrobial stewardship is crucial in the
era of growing microbial resistance. Although not yet
broadly introduced in hematology centers, it is warranted
by the resistance crisis and the scarce development of new
antibiotics, in particular those with new targets or mecha-
nisms of action or with activity versus Gram-negative
pathogens. Already, resistance developments are jeopardiz-
ing the improved outcomes for hematology patients that
have been achieved by medical advances over the last
decade. Antimicrobial stewardship aims to diminish unnec-
essary antibiotic exposure and to minimize collateral dam-
age by broad-spectrum antibiotics. Infection control meas-
ures are complementary, to prevent the spread of resistant
pathogens. De-escalation strategies have been successfully
used in other areas of medicine, including the ICU, to
decrease selection pressure by prolonged unnecessary regi-
mens of broad-spectrum antibiotics. Their multidisciplinary
implementation in hematology is much to be welcomed.
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